FDA. 2011e. Guidance: Medication guides—distribution requirements and inclusion in Risk Evaluation and Mitigation Strategies (REMS). Washington, DC: US Food and Drug Administration.

FDA. 2011f. Office of New Drugs. http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm184426.htm (accessed April 10, 2011).

FDA. 2011g. FDA significantly restricts access to the diabetes drug Avandia. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm226956.htm (accessed January 14, 2011).

FDA. 2011h. FDA fundamentals. Do you know what FDA does? http://www.fda.gov/aboutfda/transparency/basics/ucm192695.htm (accessed April 24, 2011).

FDA. 2012. Report on the performance of drug and biologics firms in conducting postmarketing requirements and commitments; availability. Federal Register 77(44):13339-13343.

FDA Science Board Subcommittee. 2011. Review of the FDA/CDER pharmacovigilance program. Washington, DC: US Food and Drug Administration.

GAO (Government Accountability Office). 2008. FDA has begun to enhance its oversight of drugs approved on the basis of surrogate endpoints. Washington, DC: Government Accountability Office. GAO. 2009. Drug safety: FDA has begun efforts to enhance postmarket safety, but additional actions are needed. Washington, DC: Government Accountability Office.

Grossman, L. A., R. A. Merrill, and P. B. Hutt. 2007. FDA jurisdiction: A matter of definition. Washington College of Law Research Paper No. 2008-38. American University Washington College of Law.

Gu, Q., C. D. Dillon, and B. V. L. 2010. Prescription drug use continues to increase: U.S. prescription drug data for 2007-2008. Atlanta, GA: Centers for Disease Control and Prevention.

Hamburg, M. A., and J. M. Sharfstein. 2009. The FDA as a public health agency. New England Journal of Medicine 360(24):2493-2495.

HHS (US Department of Health and Human Services). 2010. HIPAA Mini-Sentinel and Sentinel. Washington, DC: Department of Health and Human Services.

Hilts, P. J. 2003a. Thalidomide. In Protecting America’s health. New York: Alfred A. Knoff. Pp. 144-165.

Hilts, P. J. 2003b. The modern plague. In Protecting America’s health. New York: Alfred A. Knoff. Pp. 236-254.

IOM (Institute of Medicine). 2002. Responsible research: A systems approach to protecting research participants. Washington, DC: The National Academies Press.

IOM. 2004. Patient safety: Achieving a new standard for care. Washington, DC: The National Academies Press.

IOM. 2007a. The future of drug safety: Promoting and protecting the health of the public. Washington, DC: The National Academies Press.

IOM. 2007b. Understanding the benefits and risks of pharmaceuticals: Workshop summary. Washington, DC: The National Academies Press.

IOM. 2010a. Evaluation of biomarkers and surrogate endpoints in chronic disease. Washington, DC: The National Academies Press.

IOM. 2010b. Ethical issues in studying the safety of approved drugs: A letter report. Washington, DC: The National Academies Press.

Jenkins, J. K. 2010. Memorandum from John Jenkins to Janet Woodcock (dated September, 2010). Re: Recommendations for regulatory actions—rosiglitazone. Washington, DC: Food and Drug Administration.

Lomas, J. 2005. Using research to inform healthcare managers’ and policy makers’ questions: From summative to interpretive synthesis. Health Policy 1(1):55-71.

Marks, H. M. 1997a. Playing it safe: The Federal Food, Drug and Cosmetic Act of 1938. In The progress of experiment: Science and therapeutic reform in the United States, 1900-1990. Cambridge, NY: Cambridge University Press. Pp. 136-163.